Beijing Second Pharmaceutical Signs Collaborative Agreements With Foreign Firms
This article was originally published in PharmAsia News
Executive Summary
Beijing Second Pharmaceutical, a subsidiary of Beijing Pharmaceutical Group, has signed a series of collaborative agreements to speed up its globalization strategy. These include: a new partnership with U.S. Frontage Laboratories to expand cooperation of generic drug R&D; a three-party agreement with Poland-based Adamed and Beijing CoSci Med-Tech on drug R&D, import and export registration, outsourced manufacturing and marketing, as well as cGMP authentication application; and a collaboration with an American pharmaceutical distributor to prepare for Beijing Second's product launch in the U.S. With the agreements signed and ready to be executed, Beijing Second can look forward to launching its pharmaceutical formulations internationally. (Click here for more - Chinese Language)